{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bansal GP"],"funding":["HHS | National Institutes of Health","NIAID NIH HHS"],"pagination":["e0037423"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10929423"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["92(3)"],"pubmed_abstract":["Gamete surface protein P48/45 has been shown to be important for male gamete fertility and a strong candidate for the development of a malaria transmission-blocking vaccine (TBV). However, TBV development for <i>Plasmodium vivax</i> homolog Pvs48/45 has been slow because of a number of challenges: availability of conformationally suitable recombinant protein; the lack of an <i>in vivo</i> challenge model; and the inability to produce <i>P. vivax</i> gametocytes in culture to test transmission-blocking activity of antibodies. To support ongoing efforts to develop Pvs48/45 as a potential vaccine candidate, we initiated efforts to develop much needed reagents to move the field forward. We generated monoclonal antibodies (mAbs) directed against Pvs48/45 and characterized putative functional domains in Pvs48/45 using recombinant fragments corresponding to domains D1-D3 and their biological functionality through <i>ex vivo</i> direct membrane feeding assays (DMFAs) using <i>P. vivax</i> parasites from patients in a field setting in Brazil. While some mAbs partially blocked oocyst development in the DMFA, one mAb caused a significant enhancement of the infectivity of gametocytes in the mosquitoes. Individual mAbs exhibiting blocking and enhancing activities recognized non-overlapping epitopes in Pvs48/45. Further characterization of precise epitopes recognized by transmission-reducing and -enhancing antibodies will be crucial to design an effective immunogen with optimum transmission-reducing potential."],"journal":["Infection and immunity"],"pubmed_title":["Transmission-reducing and -enhancing monoclonal antibodies against <i>Plasmodium vivax</i> gamete surface protein Pvs48/45."],"pmcid":["PMC10929423"],"funding_grant_id":["R03AI111138","R01AI47089","R01 AI047089","R01 AI127544","U19AI089681","R01AI-27544","R03 AI111138","U19 AI089681"],"pubmed_authors":["Araujo MdS","Bansal GP","Araujo JE","Vinetz J","Cao Y","Hayashi C","Kumar N","Medeiros JF","Shaffer E"],"additional_accession":[]},"is_claimable":false,"name":"Transmission-reducing and -enhancing monoclonal antibodies against <i>Plasmodium vivax</i> gamete surface protein Pvs48/45.","description":"Gamete surface protein P48/45 has been shown to be important for male gamete fertility and a strong candidate for the development of a malaria transmission-blocking vaccine (TBV). However, TBV development for <i>Plasmodium vivax</i> homolog Pvs48/45 has been slow because of a number of challenges: availability of conformationally suitable recombinant protein; the lack of an <i>in vivo</i> challenge model; and the inability to produce <i>P. vivax</i> gametocytes in culture to test transmission-blocking activity of antibodies. To support ongoing efforts to develop Pvs48/45 as a potential vaccine candidate, we initiated efforts to develop much needed reagents to move the field forward. We generated monoclonal antibodies (mAbs) directed against Pvs48/45 and characterized putative functional domains in Pvs48/45 using recombinant fragments corresponding to domains D1-D3 and their biological functionality through <i>ex vivo</i> direct membrane feeding assays (DMFAs) using <i>P. vivax</i> parasites from patients in a field setting in Brazil. While some mAbs partially blocked oocyst development in the DMFA, one mAb caused a significant enhancement of the infectivity of gametocytes in the mosquitoes. Individual mAbs exhibiting blocking and enhancing activities recognized non-overlapping epitopes in Pvs48/45. Further characterization of precise epitopes recognized by transmission-reducing and -enhancing antibodies will be crucial to design an effective immunogen with optimum transmission-reducing potential.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-04T05:30:31.737Z","creation":"2025-04-06T14:34:50.78Z"},"accession":"S-EPMC10929423","cross_references":{"pubmed":["38289124"],"doi":["10.1128/iai.00374-23"]}}